Shire's INTUNIV (Guanfacine) extended release in children with ADHD and oppositional symptoms
San Francisco, CA May 18, 2009 Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced new findings on INTUNIV
(guanfacine) extended release, a selective alpha-2A-agonist, at a major psychiatric meeting. This randomized placebo controlled trial met i...
Shire investigational nonstimulant INTUNIV showed significant efficacy in reducing ADHD symptoms
WASHINGTON, May 7 -- Shire plc(LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company,
presented today at a major scientific meeting findings from analyses of
pivotal trial results of INTUNIV, a selective alpha-2A-agonist. This compound
is an investigational once-daily medic...
FDA Approves INTUNIV (guanfacine) for the Treatment of ADHD
Shire announced today that it has received an approvable letter from the US Food and Drug Administration (FDA) for INTUNIV
(guanfacine) extended release tablets (previously referred to as SPD503), a nonstimulant selective alpha-2A-receptor agonist, which has been studied in children and adolescent...
INTUNIV in Medical Technology
INTUNIV in Biological Technology